Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

233
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
233
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Real-time quaking-induced conversion assays for prions: Applying a sensitive but imperfect test in clinical practice.

European journal of neurology·2023
Same author

Schwann cells and myelin in human peripheral nerve: Major protein components vary with age, axon size and pathology.

Neuropathology and applied neurobiology·2023
Same author

A 66-Year-Old Woman with a Progressive, Longitudinally Extensive, Tract Specific, Myelopathy.

Case reports in neurological medicine·2016
Same journal

Diagnosis and management of frontotemporal dementia: a narrative review.

Neurodegenerative disease management·2026
Same journal

Supporting gastrostomy decision-making in motor neurone disease (MND): an Australian survey of healthcare professionals' beliefs, practices, and needs.

Neurodegenerative disease management·2026
Same journal

Association between influenza infection and subsequent Parkinson's disease diagnosis: a systematic review and meta-analysis.

Neurodegenerative disease management·2026
Same journal

Association of self-efficacy and self-management with multiple sclerosis patients' quality of life: a descriptive-analytical study.

Neurodegenerative disease management·2026
Same journal

Bright light therapy for depression and excessive daytime sleepiness in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials with dose-response meta-regression.

Neurodegenerative disease management·2026
Same journal

Functional bowel disorders in idiopathic Parkinson's disease: a Rome IV-based controlled study.

Neurodegenerative disease management·2026
查看所有相关文章

相关实验视频

Updated: Jun 12, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.2K

托弗森用于SOD1 ALS的治疗.

William H Everett1,2, Robert C Bucelli1

  • 1Department of Neurology, Washington University School of Medicine, Saint Louis, MO 63110, USA.

Neurodegenerative disease management
|September 27, 2024
PubMed
概括
此摘要是机器生成的。

托弗森是一种针对肌缩侧面硬化症 (ALS) 的新疗法,其向的是SOD1突变. 虽然III期试验失败了其主要目标,但进一步的数据表明,它可能会减缓SOD1-ALS患者的疾病进展.

关键词:
降解MRNA的降解在SOD1中,SOD1是SOD1.骨髓缩侧面硬化症 (ALS) 是一种这是一种反意义的寡核酸.埃达拉沃尼是一个人瑞卢 (riluzole) 是一种药物.二甲酸 - 二甲酸 - 二甲酸 - 二甲酸这就是为什么我们要去fersen.

更多相关视频

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.6K
MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

13.9K

相关实验视频

Last Updated: Jun 12, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.2K
A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.6K
MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

13.9K

科学领域:

  • 神经退行性疾病的神经退行性疾病
  • 阿尔茨海默病的遗传学
  • 橄核酸的治疗药物

背景情况:

  • 肌缩侧面硬化症 (ALS) 是一种复杂的神经退行性疾病,患者群体异质,使临床试验设计复杂化.
  • 基因突变,特别是在SOD1中,为ALS提供了更均的治疗策略的目标.
  • 功能获取的SOD1突变是已知的家族性ALS的原因,使SOD1成为基因沉默疗法的可行目标.

研究的目的:

  • 为了评估tofersen的疗效,一个反感性寡核酸,在治疗SOD1突变ALS.
  • 评估托弗森对ALS生物标志物和疾病进展的影响.
  • 探索针对特定ALS亚型的向基因疗法的潜力.

主要方法:

  • 托弗森是一种反感性寡核酸,用于减少SOD1基因表达.
  • 作用机制是SOD1mRNA的RNA酶介导的降解.
  • 为了收集数据,进行了III期试验和随后的开放式扩展.

主要成果:

  • 托弗森对ALS生物标志物表现出显著影响.
  • 第三阶段试验的主要终点未达到.
  • 开放式扩展数据表明,SOD1-ALS患者的疾病进展减缓.

结论:

  • 使用托弗森的向基因降低疗法显示,它有望减缓SOD1-ALS的疾病进展.
  • 尽管在最初的试验中没有达到主要终点,但托弗森的生物标志物效应和观察到的进展减缓需要进一步调查.
  • 反感性寡核酸治疗代表了ALS的基因定义亚型的潜在治疗途径.